Newsletter Archive

  • Transporter Models Version 2 out now!
    on October 27, 2020

    Transporter Models Version 2 out now! The Phenaris team is delighted to announce the release of version 2 of our transporter models. VERSION 2 OF PHENARIS TRANSPORTER MODELS IS NOW AVAILABLE Register for our Webinar! We are delighted to announce the release of version 2 of our transporter models. With the addition of three new transporter (OCT1, OCT2, MATE1), we are now offering models for 8 transporter which are involved in drug/drug interactions and hepatotoxicity. Furthermore, we modified the input layout to allow easier bulk selection of models. Feel free to register for our Webinar on November 24th, 2020 at 16:00 CET to learn more about our transporter Models. Webinar Registration The Phenaris Transporter Models can predict ligand-transporter interaction in 3 easy steps: log-in, upload SDF files, run prediction. Our model portfolio is constantly updated and expanded. Version 1 already included prediction of inhibitors of P-glycoprotein, BCRP, BSEP, MRP3, OATP1B1, and OATP1B3.  For accessing the models, we […]

  • News, Articles, Product Updates - October 2020
    on October 5, 2020

    News, Articles, Product Updates - October 2020 Check out the latest updates from Phenaris! News, Articles, Product Updates October 2020 P-glycoprotein (MDR1, ABCB1) the prototypic polyspecific ABC-transporter P-glycoprotein (P-gp) is a transmembrane, ATP-driven transport protein which transports a wide variety of xenobiotics across cellular membranes and actively pumps them out of cells. It is one of 48 members of the ABC-transporter (ATP binding cassette) family. Furthermore, its expression in almost all barrier tissues in the human body, such as the gut, the blood-brain barrier, the blood-placenta barrier, and important organs like the liver outlined its major role in drug-drug interactions. Accordingly, the US Food and Drug Administration and the European Medicines Agency recommend testing for every drug candidate for clinical drug interaction studies due to interaction with P-glycoprotein. For the medicinal chemist, designing in or designing out P-glycoprotein substrate and/or inhibitor properties became an important task in lead optimisation. Thus, anticancer drugs as […]

  • ToxPHACTS & Transporter Models now LIVE!
    on February 13, 2020

    ToxPHACTS & Transporter Models now LIVE! We officially released 2 new platforms. Find out how to receive exclusive access.  View this email in your browser Request your access now and receive a 50% discount With a state of the art user interface this software enables you to predict toxicities through similarity search and data extraction. Get clearly visualized data you can easily analyze within a couple of clicks. ToxPHACTS offers the following advanced features:  Performing a similarity search using multiple algorithms Ability to export the heat-map as CSV file detailed knowledge based target-toxicity associations We offer 3 competitive pricing models (Academia, SME, Enterprise) and our very first customers get 50% off so don’t wait […]

  • ToxPHACTS now available as Web-Service!
    on August 27, 2019

    ToxPHACTS now available as Web-Service! Our basic version of ToxPHACTS is now available as a web service, free of charge for non-commercial use! View this email in your browser OUR WEB-BASED VERSION IS NOW AVAILABLE We are excited to announce that our basic version of ToxPHACTS is now available as a web service, free of charge for non-commercial use! This expert system for toxicological read across features user friendly tools to help scientists foresee possible toxicity of new development candidates. We want to make sure it serves our customers so we are grateful for any comments and suggestions. Please feel free to test our online tool and contact us with any question or feedback.  […]

Embedded Content from other Websites
On the following page we would like to load and display content from third parties for you. Please confirm your consent first.
Embedded Content from other Websites
On the following page we would like to load and display content from third parties for you. Please confirm your consent first.